Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Clinical trial NCT01200589 · TERMINATED
Trial details
- NCT number
- NCT01200589
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-11
- Primary completion
- 2016-12-19
- Enrollment
- 438
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.